Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network
肝硬化结果预防的策略和治疗:STOP-C 肝硬化网络
基本信息
- 批准号:10690121
- 负责人:
- 金额:$ 18.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-23 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:Alcoholic Liver DiseasesBehavioralBiological MarkersCessation of lifeCholestasisCirrhosisClinicalClinical DataClinical TrialsClinical Trials DesignCohort StudiesComplexCryptogenic cirrhosisDataData SetDevelopmentDisease ProgressionEffectivenessElectronic Health RecordEtiologyFatty acid glycerol estersFutureGenerationsHealthHepaticHepatotoxicityHumanIncidenceIndividualInflammationInterventionIntervention TrialKnowledgeLeadLifeLipidsLipoproteinsLiverLiver CirrhosisLiver diseasesLow-Density LipoproteinsMalignant neoplasm of liverMeasurementMediatingMeta-AnalysisMetabolicMetabolismMorbidity - disease rateOutcomePathway interactionsPatientsPersonsPharmaceutical PreparationsPhasePhenotypePlacebosPlayPopulationPortal HypertensionPravastatinPreventionPrimary carcinoma of the liver cellsProprotein ConvertasesProspective StudiesProspective cohortProspective cohort studyRandomizedRandomized Controlled TrialsReportingResearchResourcesRetrospective StudiesRiskRisk FactorsRoleSafetySerumSubtilisinsTestingTranslational ResearchUnited StatesValidationbasebehavioral outcomebiomarker discoverychronic liver injuryclinical centerclinical predictorsclinically relevantcohortcomorbiditydisorder riskendothelial dysfunctionfibrogenesishigh riskimprovedimproved outcomeinflammatory markerinhibitorinnovationinsightlipid metabolismliver allograftliver transplantationmicrobiomemortalitynon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovelnovel therapeuticspredictive modelingpreventprospectivesafety studytherapy outcomevirtualvirtual world
项目摘要
Project Summary/Abstract:
Cirrhosis and its complications including hepatocellular carcinoma (HCC) are increasingly common causes of
morbidity and mortality in the United States. The central hypotheses of this application are that (1) the creation
of a prospective cohort study of patients with compensated cirrhosis will facilitate the generation of novel
prediction models based on the clinical, behavioral, metabolic, and biomarker data we collect to predict clinical
decompensation, (2) this cohort can validate and then be supplemented by a larger electronic health record
(EHR)-based virtual cohort, the latter of which will enable validation of electronic cirrhosis phenotypes and
subsequent analysis of real-world data on the safety and effectiveness of individual lipid-lowering agents on
multiple outcomes among patients with cirrhosis and (3) long-term statin therapy will provide clinical benefits in
preventing hepatic decompensation and HCC independent of its lipid lowering effect. To investigate these
hypotheses, we propose unique approaches to both the cohort study and statin-based clinical trial for the Liver
Cirrhosis Network (LCN). In Aim 1a, we will create a prospective cohort of highly phenotyped patients with
compensated NASH, ALD, cholestatic and cryptogenic cirrhosis, in order to facilitate the interrogation of
biospecimens, patient reported behaviors and outcomes, and clinical data for novel predictors of disease
progression, and to understand through serum lipoproteins measurement the complex interaction between
cirrhosis and lipid metabolism. In Aim 1b, we will create a large LCN-wide EHR-based virtual cohort of patients
with compensated cirrhosis, prospectively validate electronic phenotypes for cirrhosis and its clinical
complications with our in-person cohort, and evaluate the use, safety and effectiveness of different classes of
lipid lowering medications upon outcomes in this large real-world virtual cohort. In Aim 2, we propose to study
the safety and efficacy of statins in preventing clinical decompensation among patients with NAFLD or ALD
cirrhosis while exploring the potential pleiotropic mechanisms of statins. In this trial, patients with and without an
established non-hepatic indication for lipid lowering will be randomized to pravastatin v. alirocumab (stratum 1)
or placebo (stratum 2), respectively. This innovative approach to the statin-based clinical trial will acknowledge
the patient's baseline indication for lipid-lowering therapy, and offer an alternative lipid lowering pathway in
PCSK9 inhibition, which has similar or greater LDL-lowering potency but lacks the pleotropic effects of statins,
to allow for novel insights into mechanisms by which statins might impact outcomes independent of its effects
on lipids. Throughout the cohort and interventional trials, we will study lipoprotein metabolism, inflammatory
markers, and collect microbiome and biospecimens for future translational research to better understand the
mechanisms behind disease progression in cirrhosis and for any potential impact of pravastatin and alirocumab
on clinical outcomes. These innovative strategies therefore leverage both cohort and clinical trial designs to
maximize the knowledge gained and improve clinical outcomes among patients with cirrhosis.
项目总结/文摘:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT S BROWN其他文献
ROBERT S BROWN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT S BROWN', 18)}}的其他基金
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network
肝硬化结果预防的策略和治疗:STOP-C 肝硬化网络
- 批准号:
10492742 - 财政年份:2021
- 资助金额:
$ 18.9万 - 项目类别:
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network
肝硬化结果预防的策略和治疗:STOP-C 肝硬化网络
- 批准号:
10311423 - 财政年份:2021
- 资助金额:
$ 18.9万 - 项目类别:
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network
肝硬化结果预防的策略和治疗:STOP-C 肝硬化网络
- 批准号:
10700170 - 财政年份:2021
- 资助金额:
$ 18.9万 - 项目类别:
PEB IFN AND RIBAVIRIN VERSUS REBETRON IN HEPATITIS C
PEB IFN 和利巴韦林与 ReBETRON 治疗丙型肝炎的对比
- 批准号:
6567820 - 财政年份:2001
- 资助金额:
$ 18.9万 - 项目类别:
ADEFOVIR DIPIVOXIL FOR PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION
阿德福韦酯用于慢性乙型肝炎病毒感染患者
- 批准号:
6567828 - 财政年份:2001
- 资助金额:
$ 18.9万 - 项目类别:
相似国自然基金
Behavioral Insights on Cooperation in Social Dilemmas
- 批准号:
- 批准年份:2024
- 资助金额:万元
- 项目类别:外国优秀青年学者研究基金项目
相似海外基金
CAREER: Early-life social environments drive behavioral and neural mechanisms of development
职业:早期社会环境驱动行为和神经机制的发展
- 批准号:
2341006 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Continuing Grant
NSF PRFB FY 2023: Assessing morphological, behavioral, and genetic impacts of methylmercury on spiders.
NSF PRFB 2023 财年:评估甲基汞对蜘蛛的形态、行为和遗传影响。
- 批准号:
2305949 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Fellowship Award
A mobile health solution in combination with behavioral change approach to improve vaccination coverage and timeliness in Bangladesh: A cluster randomized control trial
移动健康解决方案与行为改变方法相结合,以提高孟加拉国的疫苗接种覆盖率和及时性:集群随机对照试验
- 批准号:
24K20168 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The role of nigrostriatal and striatal cell subtype signaling in behavioral impairments related to schizophrenia
黑质纹状体和纹状体细胞亚型信号传导在精神分裂症相关行为障碍中的作用
- 批准号:
10751224 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
ICE-TI: A Decolonized Approach to an AAS in Social and Behavioral Sciences
ICE-TI:社会和行为科学中 AAS 的非殖民化方法
- 批准号:
2326751 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Continuing Grant
Differentiating innate and conditioned fear in behavioral level using pupillometry and neural level using brain-wide traveling wave
使用瞳孔测量法区分行为水平上的先天性恐惧和条件性恐惧,并使用全脑行波区分神经水平上的先天性恐惧和条件性恐惧
- 批准号:
23K28389 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
CAREER:HCC: Using Virtual Reality Gaming to Develop a Predictive Simulation of Human-Building Interactions: Behavioral and Emotional Modeling for Public Space Design
职业:HCC:使用虚拟现实游戏开发人类建筑交互的预测模拟:公共空间设计的行为和情感建模
- 批准号:
2339999 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Continuing Grant
Bilingualism as a cognitive reserve factor: the behavioral and neural underpinnings of cognitive control in bilingual patients with aphasia
双语作为认知储备因素:双语失语症患者认知控制的行为和神经基础
- 批准号:
10824767 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Collaborative Research: Behavioral Science and the Making of the Right-Reasoning Public Health Citizenry
合作研究:行为科学与正确推理的公共卫生公民的培养
- 批准号:
2341512 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Continuing Grant
Collaborative Research: Behavioral Science and the Making of the Right-Reasoning Public Health Citizenry
合作研究:行为科学与正确推理的公共卫生公民的培养
- 批准号:
2341513 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Continuing Grant